Scandinavian ChemoTech's subsidiary Vetiqure AB receives a first order from Hasvet Medikal AS
Scandinavian ChemoTech's subsidiary Vetiqure AB has today received a first order from the Turkish distributor Hasvet Medikal AS ”Hasvet”. The order value amounts to EUR 11,200.
The order follows the exclusive distributor agreement between Vetiqure and Hasvet that was previously communicated. Through the order, Hasvet can begin marketing in Turkey and demonstrate the benefits of vetIQure´sTM Tumour Specific Electroporation (TSE) technology to the many clinics the company covers. According to Hasvet, Hasvet's market share today amounts to 80% of the Turkish veterinary medicine market, which creates favourable conditions for effective marketing.
Hasvet did not have to wait for a long registration process to place this order. This is because the regulations in veterinary medicine are usually significantly simpler than those that apply to human medicine. In addition, four of Hasvet's employed veterinarians are trained and certified on the vetIQureTM system as a result of Vetiqure visiting the company during the winter in connection with the technology being evaluated.
"It is gratifying to see that Hasvet is so energetic about starting the launch in Turkey where interested clinics have already contacted us. When we informed them yesterday that Hasvet is now our local distributor, they were very impressed and happy. We now hope that they will soon carry out TSE treatments in Turkey and that we will soon see more and larger orders." - says Mohan Frick, CEO of Scandinavian ChemoTech AB
About Hasvet
Hasvet was founded in 1996 with the aim of importing, selling and reselling services of veterinary Medikal devices. Over the years, they have never deviated from their focus on animal health. The company has always offered innovative and creative products to veterinarians for animal health purposes.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-08-2022 11:00 CET.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
